Geraldine O'Sullivan Coyne

Geraldine O'Sullivan Coyne

UNVERIFIED PROFILE

Are you Geraldine O'Sullivan Coyne?   Register this Author

Register author
Geraldine O'Sullivan Coyne

Geraldine O'Sullivan Coyne

Publications by authors named "Geraldine O'Sullivan Coyne"

20Publications

350Reads

46Profile Views

1PubMed Central Citations

Cediranib phase-II study in children with metastatic alveolar soft-part sarcoma (ASPS).

Pediatr Blood Cancer 2019 Sep 10:e27987. Epub 2019 Sep 10.

Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.27987DOI Listing
September 2019

A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas.

Oncologist 2018 11 31;23(11):1269-e125. Epub 2018 May 31.

Early Clinical Trials Development Program, Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/lookup/doi/10.1634/th
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2018-0203DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291327PMC
November 2018

Hidradenitis Suppurativa-Like Lesions Associated with Pharmacologic Inhibition of Gamma-Secretase.

J Invest Dermatol 2018 04 11;138(4):979-981. Epub 2017 Nov 11.

Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2017.09.051DOI Listing
April 2018

Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.

Curr Probl Cancer 2017 May - Jun;41(3):182-193. Epub 2017 Feb 11.

Division of Cancer Treatment and Diagnosis, Developmental Therapeutics Clinic, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.currproblcancer.2017.02.001DOI Listing
March 2018

MABp1 for the treatment of colorectal cancer.

Expert Opin Biol Ther 2017 09 10;17(9):1155-1161. Epub 2017 Jul 10.

b Medical Oncology Service , Clinica Alemana De Santiago,universidad Del Desarrollo , Santiago , Chile.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2017.1347631DOI Listing
September 2017

Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).

J Clin Oncol 2017 May 28;35(14):1561-1569. Epub 2017 Mar 28.

Shivaani Kummar, Geraldine O'Sullivan Coyne, Khanh T. Do, Baris Turkbey, Paul S. Meltzer, Eric Polley, Peter L. Choyke, Robert Meehan, Yvonne Horneffer, Ann Lih, Amul Choudhary, Sandra A. Mitchell, Lee J. Helman, James H. Doroshow, and Alice P. Chen, National Cancer Institute, National Institutes of Health, Bethesda; and Rasa Vilimas and Lamin Juwara, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.1994DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455706PMC
May 2017

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.

Lancet Oncol 2017 05 31;18(5):587-598. Epub 2017 Mar 31.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30239-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387686PMC
May 2017

PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.

Drugs 2017 Feb;77(2):113-130

Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-016-0688-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266774PMC
February 2017

Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials.

Semin Oncol 2016 08 14;43(4):446-52. Epub 2016 Jun 14.

National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2016.06.002DOI Listing
August 2016

Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy.

Curr Opin Oncol 2015 Nov;27(6):475-81

aDivision of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland bDivision of Medical Oncology, Department of Medicine, Stanford University, Stanford, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000238DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636335PMC
November 2015

Adding fuel to the fire: immunogenic intensification.

Hum Vaccin Immunother 2014 ;10(11):3306-12

a Genitourinary Malignancies Branch; Medical Oncology Service; National Cancer Institute; National Institutes of Health ; Bethesda , MD USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/21645515.2014.973318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514022PMC
October 2015

An overview of the NCI precision medicine trials-NCI MATCH and MPACT.

Chin Clin Oncol 2015 Sep;4(3):31

Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg 31, Rm 3A44, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2304-3865.2015.08.01DOI Listing
September 2015

Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.

Expert Opin Drug Saf 2015 Jan 25;14(1):97-110. Epub 2014 Oct 25.

National Cancer Institute, National Institutes of Health National, Center for Cancer Research , Maryland, USA10 Center Dr, 12N226, Bethesda, MD 20892 , USA +1 301 496 4916 ; +1 301 402 0172 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14740338.2014.973400DOI Listing
January 2015

Immune play: defending the liver.

Hepat Oncol 2015 Jan 12;2(1):15-18. Epub 2015 Jan 12.

Gastrointestinal Malignancy Section, Thoracic & GI-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/hep.14.35DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095429PMC
January 2015

Our experts highlight the most important research articles across the spectrum of topics relevant to the field of hepatic oncology.

Hepat Oncol 2014 Oct 11;1(4):359-360. Epub 2014 Dec 11.

Gastrointestinal Malignancy Section, Thoracic & GI-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/hep.14.28DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095147PMC
October 2014

Clinical experience with ramucirumab : outcomes in breast cancer.

Expert Opin Biol Ther 2014 Sep 12;14(9):1351-60. Epub 2014 Jul 12.

National Cancer Institute, National Institutes of Health National, Center for Cancer Research, Medical Oncology Service , 12N226, Bethesda, MD 20892 , USA +1 301 496 4916 ; +1 301 402 0172 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2014.939069DOI Listing
September 2014

Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.

Expert Opin Drug Saf 2012 Jul 14;11(4):643-50. Epub 2012 Jun 14.

Mater Misericordiae University Hospital, Department of Medical Oncology, Eccles St, Dublin 7, Ireland.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/14740338.2012.69
Publisher Site
http://dx.doi.org/10.1517/14740338.2012.698608DOI Listing
July 2012